Multi-herb formulations modulating gut microbiota: A systematic review and data-driven analysis.

J EthnopharmacolJun 19, 2026 (epub)
Clinical ResearchGastroenterology

Min-Seok Cho, In-Seon Lee, Junsuk Kim et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review analyzed 29 clinical trials involving 954 participants to assess how multi-herb formulations affect gut microbiota. The study found that formulas containing Scutellaria baicalensis Georgi were linked to reductions in Escherichia-Shigella, while Zingiber officinale Roscoe showed mixed effects. The model achieved a mean accuracy of 0.84.

Key findings

  • Formulas with Scutellaria baicalensis Georgi were associated with reductions in Escherichia-Shigella.
  • Formulas containing Zingiber officinale Roscoe showed both increases and decreases in various taxa.
  • The analysis achieved a mean accuracy of 0.84 in cross-study pattern recognition.
  • A macro F1-score of 0.42 indicates limited but informative recognition of patterns.

Why it matters

Understanding how multi-herb formulations influence gut microbiota can inform the development of standardized treatments in ethnopharmacology, potentially enhancing therapeutic outcomes in various disease contexts.

Source

PubMed · PMID 42320776

Published in J Ethnopharmacol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.